Home / Intelligence /

Search

Webinars

Gene Therapy Uptake: The Elephant in the Room

Available On Demand

How can companies maximize their potential when launching a gene therapy product? Gene therapy commercialization is in its infancy. Limited commercial precedent creates significant difficulty in modeling gene therapy revenue and uptake. The single administration nature of the products also presents a unique challenge for companies as the eligible patient population decreases over time. In this webinar, Trinity Life Sciences’ cell and gene therapy experts evaluate the factors that are unique to forecasting gene therapy markets and share what companies…

Watch Now

White Papers

Gene Therapy Uptake: The Elephant in the Room

Gene therapies’ single administration nature presents a unique commercial challenge for biopharmaceutical companies; unlike traditional small molecule or biologic therapies that can be dosed chronically or repeatedly on an “as needed” basis, the one-time per patient administration of a gene therapy means that as time passes, the eligible population decreases in size. In this white paper, Trinity Life Sciences’ cell and gene therapy experts explore the unique opportunities that life sciences executives can utilize to unlock eligible patient populations and…

Read Now

Webinars

Valuing an Early-Stage Asset in Pharma and Biotech: Innovative Approaches for Novel Therapies

Available On Demand

Secure success in bringing your novel therapies to market with Trinity’s innovative, holistic approach to valuing early-stage assets. Biopharma companies have been experiencing record levels of growth in recent years through M&A, co-developments, joint ventures, licensing agreements and other partnership deals. It is unlikely that this accelerated growth would have been sustained using traditional methodologies that are less able to generate realistic valuations for complex innovative therapies. Using traditional valuation methods, we likely would not have seen the commercialization of…

Watch Now

Blog

Mapping the Unknown: Measuring Cell and Gene Therapy Adoption Using Real-World Evidence

Published August 9, 2022

It’s been 10 years since the first pediatric patient was treated with chimeric antigen receptor T-cell (CAR-T) therapy for her acute lymphoblastic leukemia. At the time, the approach to engineer immune cells was a novel, ground-breaking concept. In the subsequent decade, research into this space had continued to advance. Equally importantly, the patient has remained cancer-free, serving as one of the most visible examples of the impact this type of therapeutic may have for patients with complex or difficult to…

Read Now

White Papers

Valuing an Early-Stage Asset in Pharma and Biotech

In 2018, Trinity Life Sciences published a white paper titled, How to Approach Asset Valuation in Pharma & Biotech: Putting a price tag on emerging therapies. At the time, pharma and biotech firms were seeing venture investment growth of ~20% per year. This trend has only accelerated alongside the value of co-developments, partnerships, joint ventures, licensing agreements and other deals nearly doubling from 2019 to 2020. Quantifying the value of underlying assets throughout the clinical development process remains vital to…

Read Now

Scientific Publications

Trends in Cell and Gene Therapy Uptake and Utilization in the United States: A Real-World Analysis of the Komodo Healthcare Map™ claims Data from 2015-2021

OBJECTIVES: Cell and gene therapies (CGT) have prompted innovation in the life sciences landscape and captured national attention. However, the real-world use across this therapeutic class is not well quantified. This study aims to evaluate CGT uptake and quantify utilization patterns in the US, from 2015-2021. METHODS: This study analyzed patient-level US claims data in the Komodo Healthcare Map™, a dataset including longitudinal medical and prescription claims encompassing adjudicated claims of >150 million unique enrollees from the US commercial, Medicare,…

Read Now

Blog

Cell and Gene Therapy Landscape: Challenges and Opportunities for Biotech and Investors

Published October 19, 2021

Executive Summary The American Society of Cell & Gene Therapy (ASCGT) wrapped up their 2021 conference earlier this year, which covered a range of topics, from new scientific advances to the evolving pricing and market access dynamics surrounding cell and gene therapies (CGT). Trinity had the opportunity to attend the conference, which brought together stakeholders from across the CGT landscape to discuss some of the challenges and opportunities within the space today. In this post we will cover the most…

Read Now

Blog

Assessing the Value of Non-Curative Cell and Gene Therapies

Published October 6, 2021

Executive Summary Given the majority of cell and gene therapies to date have offered the potential of a cure, pricing and access considerations are likely to differ for non-curative agents that are entering this space Although non-curative cell and gene therapies have demonstrated clinical efficacy (e.g., for multiple myeloma and wet age-related macular degeneration), manufacturers will need to communicate additional value offerings of these therapies to payers in order to avoid pushback and enhance access potential, such as: Robust evidence…

Read Now

Case Studies

Global Value Messaging and P&MA Strategy for a CAR-T Cell Therapy

Trinity completed an engagement to support the successful launch of a CAR-T cell therapy with distinct clinical profile in a competitive landscape. Geographic Scope: Client Situation The client asked Trinity to develop and externally validate global payer value messages and the associated evidence set for their CAR T cell therapy. They also required support with developing a robust global pricing and market access strategy for their asset. Trinity’s Solution Trinity conducted focus groups and In-Depth-Interviews (IDIs) with key payer and provider stakeholders in scope markets to understand…

Read Now

Blog

The Future of Cell Therapy: What’s Next?

Published November 3, 2020

Executive Summary Cell-based therapies are emerging as a promising strategy for cancer and are generating a lot of interest both academically and industrially To date, cell therapies have been approved in the US by the Food and Drug Administration (FDA) with them showing a lot of promise in a limited number of solid tumors although they have not yet progressed to FDA approval There have been multiple challenges involved when trying to successfully commercialize the products, but the landscape looks…

Read Now